Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors
- 1 February 2000
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (3), 237-242
- https://doi.org/10.1097/00002030-200002180-00005
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudineThe Lancet, 1998
- RitonavirClinical Pharmacokinetics, 1998
- P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.JCI Insight, 1996
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.JCI Insight, 1995
- Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugsCell, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- ABC Transporters: From Microorganisms to ManAnnual Review of Cell Biology, 1992
- Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cellsCell, 1991
- Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.Journal of Histochemistry & Cytochemistry, 1990
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1976